Research Consortium Aims to Accelerate Progress in Kidney Cancer Management
Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.
EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET
Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.
Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer
A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.
Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma
Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.
Elironrasib Earns FDA Breakthrough Designation for KRAS G12C-Mutant NSCLC
The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.
XmAb819 Targets Highly Expressed Protein in Clear Cell Renal Cell Carcinoma
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers
Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.
Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.
Novel CAR T-Cell Therapy Prioritizes Immune-Restoring Capability in RCC
“The therapy is designed to prevent CAR T-cell inactivation and to restore the antitumor immunity of the white blood cells that have gotten through the tumor,” said Wayne A. Marasco, MD, PhD.
DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC
Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.
EC Approves Ibrutinib Plus Chemoimmunotherapy +/- ASCT in Untreated MCL
Results from the phase 3 TRIANGLE trial showed prolonged failure-free survival and overall survival with ibrutinib and CIT vs CIT plus ASCT alone.
Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma
Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.
Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer
Data from the phase 3 KEYNOTE-A18 trial support the approval of the pembrolizumab-based regimen for those with stage III to IVA cervical cancer in Canada.
European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL
Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Exploring Novel Therapeutic Combination Strategies in Kidney Cancer
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
A Decade of Research Led to Reduced Toxicity With Novel CAR T-Cell Therapy in RCC
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma
The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.
Personalized Renal Vaccine Emerges as Encouraging Option in Phase 1 Study
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
Kidney Cancer Research Consortium May Advance Progress in the Field
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
FDA Gives RP1 Combo Complete Response Letter in Advanced Melanoma
The FDA indicated that data from the phase 1/2 IGNYTE trial were not adequate to provide evidence of effectiveness.
Osimertinib Combo Significantly Prolongs Survival in Advanced EGFR+ NSCLC
Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.
CAR T-Cell Therapy Targeting CAIX/CD70 May Improve Tumor Cell Killing in ccRCC
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Improved Outcomes With Nivolumab May Be Associated With CD163+ Macrophages in Metastatic RCC
New research suggests high levels of CD163-positive tumor-associated macrophages may significantly improve nivolumab efficacy in metastatic RCC.
New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity Among Oncologists
The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.
Highlighting Breast Cancer Advances at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Mirdametinib Earns Conditional European Approval in Adult/Pediatric NF1-PN
EU approval of the agent is based on results from the phase 2b ReNeu trial, which met its primary end point of confirmed objective response rate in NF1-PN.
FDA Issues CRL to Glofitamab Plus GemOx in ASCT-Ineligible R/R DLBCL
In lieu of an 8-1 ODAC ruling against the applicability of the phase 3 STARGLO results in US patients, a CRL has been issued for glofitamab in relapsed/refractory DLBCL.
Cyclophosphamide-Based GVHD Prophylaxis May Improve Survival in HSCT
Many patients reported social/financial vulnerabilities that possibly precluded them from transplant access outside of the phase 2 clinical trial.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy
David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.